Health Intervention and Technology Assessment Program

HTA is well known as a useful tool to assist health policy decision-making. As a result, there are attempts to establish HTA in Thailand in various sectors. An early attempt from governmental side was the production of a background paper on HTA for the National Public Health Assembly, later known as National Health Assembly, commissioned by Thailand’s Health System Research Institute (HSRI) to a highly respected clinical epidemiologist, Professor Dr. Chitr Sitthi-Amorn, in 1988. Following the initiation, there were attempts to create HTA agencies either inside or outside the Ministry of Public Health with the aim to use HTA to inform health policy-makings. These include at least two currently discontinued projects, namely, a collaborative project between Thailand and Sweden called Technology Assessment and Social Security in Thailand (TASSIT) and a Thailand and Australia collaboration called Setting Priorities Using Information on Cost-Effectiveness (SPICE). Another attempt was made to create Institute of Medical Research and Technology assessment (IMRTA) in the Department of Medical Services in the Ministry. The IMRTA, unlike the other two examples, continues to generate HTA evidence and build HTA capacity to these days.

Dr.Yot Teerawattanon and Dr.Sripen Tantivess, the two co-founders of HITAP, were research fellows under the mentorship of Dr. Viroj Tangcharoensathien at the International Health Policy Program (IHPP), which was then led by Dr.Suwit Wibulpolpresert, before they got scholarship to pursue their PhD in the UK. After their return in 2006, with consultation from the two mentors, the idea to initiate HITAP materialized. With a seed grant from the Thai Health Promotion Foundation (ThaiHealth) for $1,000,000 to be spent in the period of 3 years, HITAP started out with less than 10 staff with Dr.Yot as the Program Leader and Dr.Sripen as a senior researcher. To maintain the link with policy decision-making bodies without impairing its independency and flexibility, HITAP opted for two statuses: a program under IHPP in the Bureau of Policy and Strategy in the Ministry of Public Health and the HITAP Foundation which is the managing body for HITAP. While the first status keep HITAP in close contact with policy-makers, the latter allow HITAP to work to respond to the broader need in and outside to country. No government budget was allocated for HITAP nor, to avoid conflict of interest, do HITAP receive funding support from industries.

With the aim to link its work to policy decision-making, the first batch of HITAP’s research topics were derived from the list of prioritized topic compiled by policy-makers. HITAP sent out letters calling for topic nominations from policy-making bodies such as departments in the Ministry of Public Health and healthcare payers, review about the nominated topics and prioritize them according to the criteria constructed based on a literature review before presenting them to the policy-makers in a topic selection workshop for their comments and final says on the prioritized topics. With this approach, all of HITAP’s first batch HTA researches was used to inform policy decision-making, mostly for the development of the Thai pharmaceutical reimbursement called the National List of Essential Medicine (NLEM) and the Benefit Package (BP) under the Universal Coverage Scheme (UCS). This build a path to formal channel of integrating HTA to the development of both NLEM and BP later.

In operationalizing HITAP’s goals and in fulfilling its advisory role in the decision making process HITAP follows the five key strategies[5] of having an 1) HTA Fundamental System; 2) strengthening Human Capacity; 3) HTA Research; 4) Knowledge Management; and 5) creating an HTA Network.

Having an HTA fundamental system entails basic research and development for HTA or the creation of infrastructure to support health intervention and technology assessment by developing standards that are on par with the international level whilst taking into account resource constraints in the Thai context. Under this strategy, methodological guidelines,[6] a database of HTA studies in Thailand, tools and quality of life measures for cost-utility analysis, and a social value based threshold ceiling were developed. To strengthen Human Capacity is to work at the individual, institutional and system levels. To date, HITAP along with its partners have sponsored the completion of graduate studies at both the masters (17 staff) and doctoral level (8 staff) with the aim of strengthening staff technical competency for research. In addition, for stakeholders interested in HTA, training courses are organized annually for physicians, pharmacists, public health administrators, and others. HITAP’s core business is HTA Research. The strategy therefore addresses the growing demand for studies, particularly on cost-effectiveness and budget impact appraisals in Thailand. HITAP’s current body of research includes 124 published reports and publications on pharmaceuticals (26), medical devices (8), medical procedures (4), health interventions (26), health promotion and disease prevention interventions (38), health policy (8), and others (14). Through applying a knowledge management strategy and by disseminating research results to all relevant stakeholders, translation and integration of research findings into policy becomes effective. HITAP actively engages stakeholders through a variety of channels – meetings, seminars, press releases, blogs and social media including, Facebook, Twitter and online campaigns. Its fifth strategy is creating an HTA network. HITAP’s collaborations operate at the regional, national and international levels including academic institutes, health professional consortia and associations, and health providers. Notably, HITAP is in partnership with more than 20 HTA institutes in Asia and additionally involved as a core partner in the international Decision Support Initiative (IDSI) of NICE International, UK funded by the Bill and Melinda Gates Foundation.

The National Health Security Office, which institutes and manages the largest health plan in Thailand (Universal Coverage Scheme [UC]), initiated a collaborative research and development project with two independent research institutes – the Health Intervention and Technology Assessment Program and the International Health Policy Program – in 2009. The aim of the project was to develop an optimal strategy for the development of the UC benefit package, that is, to determine which interventions should be candidate for public reimbursement. The project is named research for development of health benefit package under the universal health care coverage scheme, or known as UCBP (see www.ucbp.net). The project incorporates multiple-criteria decision analysis (MCDA) and a deliberative process and multi stakeholders’ involvement to guide national-level priority setting in health care coverage decision. The review documented the experience of seven health technology assessment organizations in Canada, England and Wales, the United States, the Netherlands, Germany, Sweden and Spain, which all use an explicit process of priority setting. Its findings concluded that all these organizations consider multiple criteria, involved multiple stakeholders, and distinguish, in one way or another, four basic steps in their priority setting Process. These steps were then also applied in the Thai setting and included. The results of the review were adapted to the Thai setting, resulting in 4 steps of explicit priority setting including: 1) nomination of interventions for assessments, 2) selection of interventions for assessment, 3) technology assessment of interventions, and 4) appraisal of interventions. Since the beginning of the research project up to 119 topics have been proposed for inclusion into the benefit package, with 53 topics selected for further research or HTA analysis.

One of the benefit packages revised through UCBP is the development of a health screening package under the universal health coverage in 2010. Currently, the three public insurance schemes in Thailand offer different health screening packages. The study was designed as a response to requests from stakeholders including decision-makers and representatives from the general public, to develop an evidenced-based health screening package for the population that could ensure equitable access to essential health screening under the three schemes. The results led to advice against elements of current clinical practice, such as annual chest X-rays and particular blood test (e.g. kidney function test), and indicated that the introduction of certain new population-based health screening programs, such as for chronic hepatitis B, would provide substantial health and economic benefits to the Thais. The final results were presented to a wide group of stakeholders, including decision-makers at the Ministry of Public Health and the public health insurance schemes, to verify and validate the findings and policy recommendations. The package has been endorsed by the Thai UHC Benefit Package Committee for implementation in fiscal year 2016.

Thailand National List of Essential Medicines Process Flowchart.

In 1981, Thailand’s National List of Essential Medicines was created. Subsequently, in 1983, the Subcommittee for the Development of the National List of Essential Medicines who works in collaboration with the Food and Drug Administration as its secretariat. In the latter years, the function of the subcommittee became the maintenance of an optimal list of medicines, wherein the criteria for selection were cost, safety, efficacy and effectiveness of drugs. In each of these criteria, the subcommittee’s [7] was to consider scientific evidence to determine which medicines are to be included in the list. Twenty-eight specialist working groups undertake the task of determining what should be on the list as well as informing price negotiations between manufacturers and the NLEM.

Increasingly, awareness and realization that the evidence required for optimal coverage decisions involved analyses in cost-effectiveness as a fifth criterion. In 2009, the Health Economics Working Group was established under the subcommittee. The working group was composed of health economists, representatives from the subcommittee, academics and representatives from the three health insurance schemes and the working group secretariat. In this process, HITAP in collaboration with the Food and Drug Administration was involved as the secretariat of the working group whose function was to generate procedures and assure quality of the evidence provided. The HEWG then prioritized the requests based on burden of disease, the risk to life and financial burden on households posed by the condition and social consideration and commissions the cost-effectiveness research from non-profit agencies (like HITAP).

In late 2013 in response to the increasing requests for involvement in international projects, HITAP created the HITAP International Unit in order to collaborate with international partners and networks working to improve health intervention and technology assessment (HITA) for Universal Health Care (UHC) and priority-setting capacity in low- and middle-income countries (LMICs). The HIU draws upon the experiences of HITAP experts to match the growing demand for evidence-informed policy at the global level. Under the HIU, dedicated professionals work and collaborate to provide the means with which to build institutions dedicated towards establishing HTA and priority setting at the local, national and global levels through research, capacity building activities and knowledge products. With the vision of Building Health Technology Assessment Capacity for a Better Society engages in projects, activities and partnerships working towards the same efforts. The HIU has previously worked with the National Center for Pharmaceutical Access and Management (NCPAM), Philippines, Health Technology Assessment Committee (HTAC), Indonesia, Health Systems and Policy Institute (HSPI), Vietnam, the International Decision Support Initiative (IDSI), UK and the National Institute for Health and Care Excellence International (NI), UK.

In the past HITAP has been instrumental in pushing HTA forward in international policy by becoming part of the delegation representing Thailand as sponsors and writers of several resolutions in the World Health Assembly (WHA) and the South-East Asia Regional Office (SEARO) of the World Health Organization (WHO), including:

• Health Intervention and Technology Assessment in Support of Universal Health Coverage Agenda. 15.7 A67/VR/9, WHA 67.23 24 May 2014.[8]
• Health Intervention and Technology Assessment in Support of Universal Health Coverage. SEA/RC66/R4 May, 2014.[9]

HITAP has also worked to establish regional collaboration amongst HTA units in Asia. Along with the National Evidence-based Health Care Collaborating Agency, South Korea (NECA) and the Center for Drug Evaluation, Taiwan (CDE), HITAP founded the HTAsiaLink Network in 2010.[10] The network is a collaborative platform for knowledge sharing and best practices of HTA in the Asia-Pacific region. One of its many activities is the production of a biannual HTAsialink Newsletter and an Annual HTAsiaLink Conference held in different member countries in Asia. Currently the Network has 30 member organizations from 16 Countries. HITAP has previously organized the Framework Convention on Tobacco Control: Reflecting on a Decade of Achievement and Strengthening a Multi-Sectoral Approach to Implementation as well as co-organized the Prince Mahidol Award Conference (PMAC) 2016: Priority Setting for Universal Health Care in 2015.

• Official Website
• The Price of Life, a game on health prioritization.
• HTAsiaLink
• Global HITAP
• HITAP HTA Technical Training Courses